Alcon Inc. (NYSE: ALC) saw its stock price surge 5.02% in after-hours trading on Wednesday following the release of its third-quarter 2025 earnings report, which exceeded analyst expectations. The eye care giant reported quarterly adjusted earnings of $0.79 per share, outperforming the consensus estimate of $0.76 by 3.95%.

The company's financial results revealed solid growth across key segments. Alcon's total sales for Q3 2025 reached $2.589 billion, representing a 6% increase on a reported basis and a 5% rise in constant currency compared to the same period last year. Notably, the Surgical segment saw significant growth, with Equipment/other sales jumping 13% to $243 million, driven by recent product launches including the Unity VCS system.

Investors were particularly encouraged by Alcon's performance in the Vision Care segment, which grew 7% to $1.169 billion. The company's ocular health division showed strong momentum, with sales increasing 7% to $462 million, led by products for dry eye and glaucoma, including Systane, Tryptyr, and Rocklatan. Additionally, Alcon's CEO, David J. Endicott, expressed optimism about the company's future prospects, citing positive reception for the PanOptix Pro and early promise for the newly launched Tryptyr product.

Despite a slight decrease in the core operating margin, Alcon maintained its full-year 2025 guidance, projecting net sales between $10.3 billion and $10.4 billion, and core diluted earnings per share in the range of $3.05 to $3.15. This reaffirmation of the company's outlook likely contributed to investor confidence, driving the stock's after-hours rally.